Most aortic aneurysms produce few symptoms until rupture forces a sudden pivot to emergency care. In the United States, they account for about 15,000 deaths each year. Screening detects asymptomatic abdominal aneurysms in 80 to 90% of cases, yet rupture can bring sudden severe abdominal or back pain in 70 to 90% of patients.
Key Takeaways
- Asymptomatic AAA is detected in 80-90% of cases via screening
- The prevalence of abdominal aortic aneurysm (AAA) in men aged 65-74 years who have ever smoked is approximately 8.0%
- 30-day mortality for ruptured AAA overall is 50-80%
- Smoking increases AAA risk by 5-fold, with 80% of ruptured AAAs in current or former smokers
- Open surgical repair (OSR) is standard for AAA >5.5 cm in good-risk patients, with 30-day mortality 4-6%
Most aortic aneurysms are symptomless until rupture, so early detection and monitoring save lives.
Related reading
01 · Category
Clinical Presentation30 stats
01
Asymptomatic AAA is detected in 80-90% of cases via screening
02
Sudden severe abdominal or back pain occurs in 70-90% of ruptured AAAs
03
Pulsatile abdominal mass palpable in only 30-50% of AAA patients, higher in thin individuals
04
Hypotension and shock present in 45-60% at rupture presentation
05
Chest pain or hoarseness in 20-30% of descending TAA cases
06
Syncope occurs in 5-10% of ruptured AAA patients
07
Ultrasound sensitivity for AAA >3cm is 95-100%, specificity 96-100%
08
CT angiography detects 98% of AAAs with size accuracy ±1mm
09
Dysphagia or stridor in 10-15% ascending TAA due to compression
10
Back pain without trauma in 50% of symptomatic unruptured AAAs
11
MRI has 92-100% sensitivity for TAA diagnosis
12
Femoral pulse asymmetry in 20-30% of AAA with iliac involvement
13
Embolic events like blue toe syndrome in 5% of AAAs
14
Echocardiography screens for TAA in 85% of bicuspid valve patients
15
Aortoenteric fistula symptoms (GI bleed) in 1-2% of AAAs post-EVAR
16
Genetic testing positive in 25% of familial TAA cases
17
D-dimer >500 ng/ml elevated in 80% ruptured AAAs
18
Plain X-ray shows AAA calcification in 60-70%
19
Hoarseness (Ortner's syndrome) in 1-5% arch TAA
20
Ultrasound screening detects 4.0-5.4 cm AAA with PPV 100%
21
Acute limb ischemia in 3-5% symptomatic AAAs
22
PET-CT shows inflammation in 70% rapidly growing AAAs
23
NVUGA (non-visualized urgent groin access) unnecessary in 95% EVAR planning
24
Superior mesenteric artery syndrome symptoms in 1% large AAAs
25
Screening ultrasound false positive rate <1% for AAA
26
TAA diagnosed by echo in 90% Marfan patients annually
27
Abdominal bruit audible in 10-20% large AAAs
28
Rupture confirmed by FAST ultrasound in 85% hemodynamically unstable patients
29
Inflammatory AAA (thick wall >2mm) in 5-10%, presents with pain
30
EVAR surveillance CT detects endoleak in 20-30% at 1 year
Interpretation
Clinical Presentation Interpretation
In the clinical presentation of aortic aneurysm, most cases are discovered when asymptomatic, with 80 to 90% of AAAs found on screening, yet when rupture occurs patients often show sudden severe abdominal or back pain in 70 to 90% and hypotension or shock in 45 to 60%.
02 · Category
Epidemiology30 stats
01
The prevalence of abdominal aortic aneurysm (AAA) in men aged 65-74 years who have ever smoked is approximately 8.0%
02
Incidence rate of AAA rupture in the United States is estimated at 1.3-1.6 per 100,000 person-years
03
AAA is present in 1.1-1.4% of men aged 55-64 years and 2.0-2.6% in those aged 65-74 years screened via ultrasound
04
Thoracic aortic aneurysm (TAA) prevalence is about 10 per 100,000 persons annually
05
In a Swedish screening program, AAA prevalence was 1.3% in men aged 65 years
06
Global incidence of AAA is higher in Caucasian populations, with rates up to 4-8% in men over 65
07
AAA accounts for 15,000 deaths annually in the US, representing 0.4% of all deaths in men
08
Prevalence of AAA in women aged 65-79 is 1.0-1.3%, significantly lower than in men
09
In the UK, AAA prevalence in men over 65 is 4.4% for aneurysms ≥3.0 cm
10
Annual rupture rate for AAA 4.0-5.4 cm is 1-5%
11
Familial AAA occurs in 15-20% of cases with a first-degree relative affected
12
Incidence of TAA is 5-10 per 100,000 person-years, higher in Marfan syndrome patients at 1%
13
AAA screening uptake in eligible US men is only 10-15%
14
Prevalence of unruptured AAA discovered incidentally is 2-4% in autopsies of men over 50
15
In Japan, AAA prevalence is lower at 1.2% in men over 65 due to dietary factors
16
Ruptured AAA mortality pre-hospital is 50-70%
17
AAA incidence has declined 1.4% annually in the US from 1999-2015 due to smoking cessation
18
TAA associated with bicuspid aortic valve has prevalence of 20-30% in affected patients
19
In Olmsted County, MN, AAA incidence in men 60-74 years was 37 per 100,000 from 1987-2000
20
Global AAA rupture incidence is 5-10 per 100,000, higher in older males
21
Prevalence of AAA ≥5 cm in screened men 65-74 is 1.3%
22
Women have 4-5 fold higher rupture risk per aneurysm size compared to men
23
AAA in siblings increases risk 2-7 fold
24
Annual TAA growth rate averages 0.1-0.2 cm/year
25
In Australia, AAA prevalence in men 60-74 screened is 3.3%
26
US Medicare data shows 200,000 prevalent AAAs annually
27
TAA prevalence in general population autopsy is 0.9-3.7%
28
Rupture risk for AAA 5.5-6.0 cm is 9.4% per year in men
29
Incidence of mycotic AAA is 0.7-1.7% of all AAAs
30
In the RESCAN meta-analysis, mean AAA growth rate is 2.7 mm/year for aneurysms >5.5 cm
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, abdominal aortic aneurysm is relatively common in older men with ultrasound showing prevalence rising from about 1.1 to 1.4 percent at ages 55 to 64 and up to 2.0 to 2.6 percent at ages 65 to 74, while smoking history can push prevalence to around 8 percent.
03 · Category
Prognosis And Outcomes27 stats
01
30-day mortality for ruptured AAA overall is 50-80%
02
Elective OSR for AAA has 5-year survival 70-80%
03
EVAR 8-year aneurysm-related mortality 2.3% vs 5.2% OSR
04
AAA rupture risk at 7.0 cm diameter is 40-50% per year
05
Post-EVAR all-cause mortality at 15 years is 87%
06
TAA rupture mortality 70-90% if untreated
07
Survival benefit of screening reduces AAA mortality 40-50% at 13 years
08
Female sex increases post-EVAR mortality 2-fold adjusted
09
5-year freedom from re-intervention EVAR 73% vs OSR 86%
10
Marfan TAA 10-year survival post-TEVAR 70%
11
Age >80 years has 30-day OSR mortality 15-20%
12
Type Ia endoleak post-EVAR mortality 20-30%
13
Familial AAA has faster growth, rupture risk 1.5-fold higher
14
Long-term survival post-rupture AAA 40% at 5 years
15
TAA dissection 5-year survival 50-70% with TEVAR
16
Sac shrinkage >10mm post-EVAR in 40-50% at 5 years predicts stability
17
Comorbid CAD reduces 5-year AAA survival to 50%
18
UKSAT trial: screening halves rupture rate to 1.3/1000 vs 2.6 unscreened
19
Mycotic AAA repair 1-year survival 50-60%
20
EVAR for ruptured AAA improves 30-day survival to 35-50%
21
TAA growth >0.5 cm/year predicts rupture risk 15-20%
22
Post-OSR survival matches general population age-adjusted for first 2 years
23
Female AAA patients have 30-day rupture mortality 70-80%
24
Late rupture post-EVAR 1-2% cumulative at 10 years
25
Bicuspid TAA 10-year event-free survival 70% post-surgery
26
Inflammatory AAA has 10% higher perioperative mortality
27
90-day mortality post-TEVAR for TAA 5-10%
Interpretation
Prognosis And Outcomes Interpretation
Under the Prognosis And Outcomes lens, outcomes vary sharply by treatment and timing, with ruptured AAA carrying 30-day mortality of 50 to 80% and a 7.0 cm aneurysm risking rupture at 40 to 50% per year, while elective repair yields far better 5-year survival of 70 to 80% and EVAR shows much lower aneurysm-related mortality over the long term at 2.3% versus 5.2% with OSR.
More related reading
04 · Category
Risk Factors26 stats
01
Smoking increases AAA risk by 5-fold, with 80% of ruptured AAAs in current or former smokers
02
Hypertension contributes to 60-70% of AAA cases due to wall stress
03
Age over 65 years increases AAA risk 6-8 fold
04
Male sex is associated with 4-6 times higher AAA prevalence than females
05
Family history confers 2-4 fold increased risk for AAA development
06
Atherosclerosis is present in 90% of AAA patients
07
Current smoking doubles AAA growth rate to 0.4 cm/year vs 0.2 cm/year in non-smokers
08
Hypercholesterolemia increases AAA risk by 2.5 fold
09
Caucasian ethnicity has 2-3 times higher AAA risk than African Americans
10
Diabetes mellitus is protective, reducing AAA risk by 30-50%
11
Obesity (BMI >30) increases AAA risk by 1.5-2 fold
12
COPD increases AAA rupture risk by 2.3 fold due to coughing
13
Genetic factors account for 20-30% heritability of AAA
14
Bicuspid aortic valve increases TAA risk 20-fold
15
Marfan syndrome patients have 80% lifetime risk of TAA
16
Statin non-use increases AAA growth by 0.9 mm/year
17
Alcohol consumption >20g/day increases risk 1.5 fold
18
Peripheral artery disease coexists in 20-30% of AAA patients
19
Serum elastin peptides >1.5 ug/ml predict faster AAA growth
20
Low HDL cholesterol (<40 mg/dl) triples AAA risk
21
Connective tissue disorders like Ehlers-Danlos increase TAA risk 10-fold
22
Prior aortic surgery increases metachronous aneurysm risk 10-15%
23
HIV infection associated with 5-10% mycotic AAA incidence
24
Systolic BP >160 mmHg accelerates AAA expansion by 20%
25
Smoking cessation reduces rupture risk by 25% within 5 years
26
TGF-beta pathway mutations in Loeys-Dietz syndrome confer 95% TAA penetrance
Interpretation
Risk Factors Interpretation
For aortic aneurysm risk, the biggest pattern is that lifestyle and patient factors compound dramatically, since smoking raises AAA risk 5-fold and age over 65 boosts it 6 to 8 fold, meaning older smokers with hypertension and a family history face substantially higher likelihood of developing AAA.
05 · Category
Treatment Options26 stats
01
Open surgical repair (OSR) is standard for AAA >5.5 cm in good-risk patients, with 30-day mortality 4-6%
02
Endovascular aneurysm repair (EVAR) reduces 30-day mortality to 1.2-1.7% vs OSR
03
Beta-blockers reduce aortic wall stress by 20-30% in TAA management
04
Surveillance ultrasound every 6-12 months for AAA 4.0-4.9 cm
05
Statins reduce AAA growth by 0.5-1.0 mm/year in trials
06
ACE inhibitors slow AAA expansion by 25% in observational data
07
Fenestrated EVAR for juxtarenal AAA has technical success 95-99%
08
Smoking cessation counseling effective in 40% of AAA patients pre-op
09
TEVAR for descending TAA has 90-95% technical success
10
Blood pressure control to <120/80 mmHg recommended for TAA
11
Branched EVAR for thoracoabdominal aneurysms success 85-90%
12
Aspirin 81-325 mg daily reduces cardiovascular events by 20% in AAA surveillance
13
Endovascular sealing with Nellix device abandoned due to 10-20% migration
14
Propranolol reduces TAA growth rate by 0.1 cm/year in Marfan
15
Duplex ultrasound for EVAR surveillance detects 80% type II endoleaks
16
ARBs like losartan reduce TGF-beta signaling in Loeys-Dietz
17
Chimney EVAR for high-risk anatomy success 88%
18
Exercise therapy improves fitness in 70% AAA patients unfit for surgery
19
Doxycycline inhibits MMPs, slowing growth by 1.5 mm/year in trials
20
Hybrid repair for TAAA has 30-day mortality 7-12%
21
Yearly CT surveillance post-EVAR detects sac growth >5mm in 10%
22
Genetic counseling recommended for familial TAA with 50% inheritance risk
23
Ruptured AAA treated with EVAR has 32% mortality vs 50% OSR
24
Angiotensin receptor blockers slow TAA growth 0.2 cm/year in animal models
25
Re-intervention rate post-EVAR is 20% at 5 years
26
Valve-sparing root replacement success 95% in Marfan TAA
Interpretation
Treatment Options Interpretation
In treatment decisions for aortic aneurysms, shifting from open surgery to EVAR cuts 30 day mortality dramatically from 4 to 6 percent down to about 1.2 to 1.7 percent, while for smaller aneurysms medical strategies and surveillance aim to slow progression with measures like statins reducing growth by 0.5 to 1.0 mm per year and beta blockers lowering wall stress by 20 to 30 percent.
report visual · Breakdown
Common signs and diagnostic signals in aortic aneurysm
Aortic aneurysm presentation is often subtle, but specific symptoms and imaging findings occur at high rates—helping clinicians recognize rupture risk and confirm diagnosis.
50%
Back pain without trauma in 50% of symptomatic unruptured AAAs
50%
Comorbid CAD reduces 5-year AAA survival to 50%
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priyanka Sharma. (2026, February 13). Aortic Aneurysm Statistics. Gitnux. https://gitnux.org/aortic-aneurysm-statistics
MLA
Priyanka Sharma. "Aortic Aneurysm Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/aortic-aneurysm-statistics.
Chicago
Priyanka Sharma. 2026. "Aortic Aneurysm Statistics." Gitnux. https://gitnux.org/aortic-aneurysm-statistics.
Sources & references
14 datasets cited across this report · attribution is report-level